Impact of vitamin D serum levels on clinicopathological features and outcome in advanced pancreatic carcinoma

Multivariate
	HR		95.0% CI

Variable		Lower	upper	p-value
Age	0.994	0.962	1.028	0.7
Sex	0.896	0.614	1.309	0.5
vitamin D level	0.827	0.569	1.248	0.6
Vitamin D level insufficiency	1.233	0.777	1.975	0.3
Vitamin D level deficiency	1.062	0.646	1.746	0.8
Pathology GI	1.027	0.569	1.855	0.9
Pathology GII&GIII	0.865	0.258	2.901	0.8
Site(head)	0.804	0.539	1.197	0.2
Site(Body)	0.934	0.370	0.588	0.02
Tumor size	1.380	0.610	1.219	0.7
CA19.9	1.000	1.000	1.000	0.9
Liver metastases	0.892	0.544	1.461	0.6
Lung metastases	1.210	0.792	1.848	0.3
Peritoneal metastasis	0.545	0.364	0.816	0.003
ECOG
PS1	0.103	0.877	0.394	0.7
PS2	0.020	1.070	0.425	0.8
PS3	3.915	3.054	1.001	0.04
PS4	8.319	7.383	1.898	0.004
Treatment type	0	0	0	0

	N	Mean OS (months)		Median OS (months)		Overall Survival (OS)			p-value^†

		Estimate (95%CI)		Estimate (95%CI)		6 month	12 month	18 month
All patients	176	7.72mon	(6.95–8.48)	7.60mon	(5.60–9.59)	55.7%	26.1%	0%	-----
Vitamin D3 level
Normal	70	10.57mon	(9.48–11.65)	11.36mon	(10.10–12.63)	78.6%	44.3%	0%	<0.001
Insufficiency	50	6.77mon	(5.48–8.06)	7.03mon	(5.10–8.95)	56%	16%	0%
Deficiency	56	5.01mon	(3.82–6.20)	2.66mon	(2.14–3.19)	26.8%	12.5%	0%

Characteristics	Normal		Insufficiency		Deficiency		p-value

	(N=70)		(N=50)		(N=56)

	No.	%	No.	%	No.	%
Age (years)
Mean ±SD	57.87±7.60		61.64±4.52		64.10±8.92		<0.001^‡
Median (Range)	59 (39 – 80)		61 (52 – 75)		65 (30 – 80)
Sex
Male	43	61.4	31	62	31	55.4	0.728^‡
Female	27	38.6	19	38	25	44.6
Grade
Grade I	22	31.4	6	12	1	1.8	<0.001^‡
Grade II	45	64.3	43	68	26	46.4
Grade III	3	4.3	10	20	29	51.8
Site	32	45.7	13	26	30	53.6	0.059^‡
Head
Body	20	28.6	21	42	16	28.6
Tail	18	25.7	16	32	10	17.9
Tumor size
T1	1	1.4	0	0	0	0	<0.001^‡
T2	26	37.1	10	20	7	12.5
T3	39	55.7	30	60	21	37.5
T4	4	5.7	10	20	28	50
Site of metastasis
Peritoneal	43	61.4	28	56	38	67.9	0.452^‡
Liver	45	64.3	36	72	54	96.4	<0.001^‡
Lung	18	25.7	15	30	21	37.5	0.359^‡
Bone	0	0	3	6	0	0	0.021^‡
ECOG PS
ECOG 0	8	11.4	2	4	0	0	<0.001^‡
ECOG 1	42	60	18	36	12	21.4
ECOG 2	18	25.7	24	48	22	39.3
ECOG 3	2	2.9	5	10	16	28.6
ECOG 4	0	0	1	2	6	10.7
CA 19-9	600.35±974.71		1126.54±1342.46		1422.60±1002.65		<0.001Ÿ
Mean ±SD
Median (Range)	237.50 (21 – 6987)		745 (48 – 7896)		1459 (21 – 4928)
Treatment type
Chemotherapy	68	97.1	44	88	34	60.7	0.000
Best supportive care	2	2.9	6	12	22	39.3
Response
PR	37	52.9	8	16	5	8.9	<0.001^‡
SD	21	30	19	38	8	14.3
PD	12	17.1	23	46	43	76.8

	All

Characteristics	(N=176)

	No.	%
Age (years)
Mean± SD	60.92±7.79
Median (Range)	61 (30 – 80)
Sex
Male	105	59.7
Female	71	40.3
Grade
Grade I	29	16.7
Grade II	105	59.7
Grade III	42	23.9
Site
Head	75	42.6
Body	57	32.4
Tail	44	25
Peritoneal nodules	109	61.9
Liver metastasis	135	76.7
Lung metastasis	54	30.7
Bone	3	1.7
Treatment type Chemotherapy	146	83
Best supportive care	30	17
ECOG PS
ECOG 0	10	5.7
ECOG 1	72	40.9
ECOG 2	64	36.4
ECOG 3	23	13.1
ECOG 4	7	4
Vitamin D3 level
Normal	70	39.8
Insufficiency	50	28.4
Deficiency	56	31.8
CA 19-9
Mean ±SD	1011.46±1149.19
Median (Range)	698 (21 – 7896)
Response PR	50	28.4
SD	48	27.3
PD	78	44.3
Follow-up (months) Mean± SD	7.72±5.17
Median (Range)	7.61 (0.63 – 18.60)

Częstotliwość wydawania:: 4 razy w roku
Dziedziny czasopisma:: Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology